13.94
6.37%
+0.835
Sage Therapeutics Inc stock is currently priced at $13.94, with a 24-hour trading volume of 891.90K.
It has seen a +6.37% increased in the last 24 hours and a -18.72% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $13.13 pivot point. If it approaches the $14.04 resistance level, significant changes may occur.
Previous Close:
$13.11
Open:
$13.46
24h Volume:
891.90K
Market Cap:
$838.94M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-1.4052
EPS:
-9.92
Net Cash Flow:
$-424.74M
1W Performance:
+1.83%
1M Performance:
-18.72%
6M Performance:
-34.52%
1Y Performance:
-70.63%
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
215 First Street, Cambridge, MA
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-12-23 | Initiated | Deutsche Bank | Hold |
Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
Aug-08-23 | Downgrade | Needham | Buy → Hold |
Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-07-23 | Downgrade | Stifel | Buy → Hold |
Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-22 | Initiated | Loop Capital | Hold |
Mar-31-22 | Initiated | Berenberg | Hold |
Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
Sep-23-21 | Initiated | Needham | Buy |
Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
Apr-07-21 | Initiated | Piper Sandler | Overweight |
Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
Feb-02-21 | Resumed | Raymond James | Mkt Perform |
Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-06-20 | Initiated | Citigroup | Buy |
Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
Feb-06-20 | Initiated | Mizuho | Neutral |
Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
Dec-05-19 | Reiterated | Guggenheim | Buy |
Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
May-23-19 | Initiated | Wedbush | Outperform |
Apr-25-19 | Initiated | Jefferies | Buy |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks Investment Research
What's in Store for Biogen (BIIB) This Earnings Season?
Zacks Investment Research
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Zacks Investment Research
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Zacks Investment Research
Sage Therapeutics Inc Stock (SAGE) Financials Data
Sage Therapeutics Inc (SAGE) Revenue 2024
SAGE reported a revenue (TTM) of $91.06 million for the quarter ending March 31, 2024, a +868.87% rise year-over-year.
Sage Therapeutics Inc (SAGE) Net Income 2024
SAGE net income (TTM) was -$503.14 million for the quarter ending March 31, 2024, a +9.76% increase year-over-year.
Sage Therapeutics Inc (SAGE) Cash Flow 2024
SAGE recorded a free cash flow (TTM) of -$424.74 million for the quarter ending March 31, 2024, a +16.21% increase year-over-year.
Sage Therapeutics Inc (SAGE) Earnings per Share 2024
SAGE earnings per share (TTM) was -$8.39 for the quarter ending March 31, 2024, a +10.46% growth year-over-year.
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):